Editorials

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy

Division of Pediatric Oncology and Children’s Research Centre, University Children’s Hospital Zurich, Zurich
Division of Pediatric Oncology and Children’s Research Centre, University Children’s Hospital Zurich, Zurich
Haematologica Early view Aug 20, 2026 https://doi.org/10.3324/haematol.2026.301601